NFKB1 and plasma cell myeloma: Proteasome inhibitors (PIs; bortezomib/Bz/Velcade, carfilzomib/Cz, and Ixazomib/MLN9708/Ix) are standard-of-care/primary chemotherapeutic agents for relapsed and refractory myeloma that impede tumor metastasis and angiogenesis by accelerating unfolded protein response (UPR) and by interfering with the NF-κB-enabled regulation of cell adhesion-mediated drug resistance (1–5).